Icon 1 posted 01 January, 2009 10:18 AM Profile for oxygenbabe Send New Private Message Edit/Delete Post Reply With Quote I think Barb is right. OspA quickly shifts to OspC in the human and the type of OspC determines virulence/progression.
OspA is so highly immunogenic in humans his work seems risky to me. An OspC vaccine would be a much better idea and someone posted a study on here in beagles using the conserved part of OspC across different borrelia species, immunizing the beagles 100%.
Just seems a little odd that those who know the most about this infection would make the vaccine they did. Speaks to our incapacitation being the primary objective, if you ask me...
Posted by oxygenbabe (Member # 5831) on :
No, it's easier to work with. Osp C is trickier. My problem is that they squelched a competing Osp C vaccine years ago. Their interest was money not to incapacitate us. However they didn't think very hard about potential side effects.
Posted by david1097 (Member # 3662) on :
OSPA was worked on first. OSPC came many years later and was worked on in part by Brookhaven labs.
The the vacine was supposed to make the intial lyme guru's multi multi millionaires, thus the urgency to market and thus the push through of the vacine and modification of the test criteria.
In the end it blew up in their faces.
Posted by oxygenbabe (Member # 5831) on :
And they never "unmodified" the test criteria even after the vaccine was pulled, which is evil imo as some folks who would be CDC positive are not, for no good reason at all except a now dead vaccine.